Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00814138 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Methotrexate in Myasthenia Gravis
A Phase 2 study, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00814138 is a Phase 2 study that has completed, run by University of Kansas Medical Center. The registered enrollment target is 50 participants.
The verdict
NCT00814138, a Phase 2 study, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
Myasthenia gravis is a rare neuromuscular disorder characterized by weakness and fatigability of ocular, bulbar, and extremity musculature. The specific aim of this study is to determine if oral methotrexate is an effective therapy for myasthenia gravis (MG) patients who are prednisone dependent. Patients will be randomized to receive either methotrexate or placebo and those who are entered onto this trial will have symptoms and signs of the disease while on prednisone therapy. The hypothesis is that adding methotrexate therapy in these patients will improve the MG manifestations so that the prednisone dose can be reduced and clinical measures of MG severity will improve. Funding Source - FDA OOPD
Interventions
- OTHER Placebo
- DRUG Methotrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2009-04 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00814138
The ClinicalTrials.gov registry entry for NCT00814138 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00814138 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00814138 about?
NCT00814138 is a clinical study titled "Efficacy of Methotrexate in Myasthenia Gravis". Myasthenia gravis is a rare neuromuscular disorder characterized by weakness and fatigability of ocular, bulbar, and extremity musculature. The specific aim of this study is to determine if oral methotrexate is an effective therapy for myasthenia gravis (MG) patients who are prednisone dependent. Pa...
What is the current status of trial NCT00814138?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2009-04. Estimated completion is 2014-01.
What interventions are being tested in trial NCT00814138?
The interventions under investigation include: Placebo (OTHER), Methotrexate (DRUG).
Who is sponsoring clinical trial NCT00814138?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.